Tvardi Therapeutics earnings release, August 14, 2026

Tvardi Therapeutics, Inc. (TVRD) · Form 8-K, Item 2.02 · Filed · SEC filing

Tvardi Therapeutics Announces Second Quarter

2026 Results and

Provides Business Update

Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations

Announced ulcerative colitis (UC) as the initial disease indication for TTI-109 and will host a

KOL webinar on the clinical potential of TTI-109 in UC on August 19, 2026, at 11:00 a.m. ET

HOUSTON, TX – August 14,

2026 – Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its financial and operating results for the second quarter ended June 30, 2026, and provided a business update.

Recent Developments

Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi, stated, “Since our last quarterly report, we have made significant progress in the clinical development of our STAT3 inhibitors. Regarding our next-generation

STAT3 inhibitor, TTI-109, we were enthusiastic to see modulation of disease-relevant immune cell population even in healthy volunteers.

We believe this bodes well for the development of TTI-109 in inflammatory and proliferative diseases, like UC.”

Key Upcoming Milestones

Second Quarter 2026 Financial Results

Research and development expenses for the three months ended

June 30, 2026, were $4.0 million as compared to $5.8 million for the comparable period in 2025. The decrease was primarily driven by lower clinical costs associated with TTI-101, partially offset by higher development costs associated with TTI-109.

General and administrative expenses were $2.6 million for the three months ended June 30, 2026, as compared to $3.1 million for the three months ended June 30, 2025. The decrease was primarily driven by lower professional fees, reflecting higher accounting and consulting costs in the comparable 2025 period associated with the

Company's April 2025 merger, partially offset by higher legal and investor relations costs associated with operating as a public company.

Net loss for the three months ended June 30, 2026, was

$6.5 million, compared to net income of $4.2 million for the three months ended June 30, 2025. Net income in the prior-year period reflected a $12.7 million non-cash gain from the change in fair value of the Company's convertible notes, which converted into common stock in connection with the Company's merger with Cara Therapeutics in April 2025.

Basic and diluted net loss per share attributable to common shareholders for the three months ended June 30, 2026, were both $(0.69). Basic net income per share attributable to common shareholders for the three months ended June 30, 2025 was $0.51, and diluted net loss per share for the same period was $(1.00), reflecting the dilutive impact of the Company's convertible notes prior to their conversion into common stock in April 2025.

Cash, cash equivalents and short-term investments as of June 30,

2026, were $15.8 million, as compared to $30.8 million as of December 31, 2025. Tvardi anticipates that its existing cash, cash equivalents and short-term investments will be sufficient to fund operations, as currently planned, through the HCC topline readout into the third quarter of 2027. Advancing TTI-109 into UC and additional indications will require additional funding and IND clearance.

About Tvardi Therapeutics

Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive uncontrolled proliferation, survival and immune dysregulation. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The Company is conducting clinical trials with TTI-109 in healthy volunteers and TTI-101 in hepatocellular carcinoma (

NCT05440708).

To learn more, please visit tvarditherapeutics.com or follow us on

LinkedIn and

X

(Twitter).

Financial statements

Income Statement

Three Months Ended — (in thousands, except share and per share data, unaudited)

Three Months Ended – June 30, 2026Three Months Ended – June 30, 2025Six Months Ended – June 30, 2026Six Months Ended – June 30, 2025
Operating expenses:Research and development4,0025,8068,9138,917
Operating expenses:General and administrative2,6273,0634,7674,306
Operating expenses:Total operating expenses6,6298,86913,68013,223
Operating expenses:Loss from operations-6,629-8,869-13,680-13,223
Operating expenses:Interest income172377419652
Operating expenses:Other income, net12,6597,159
Operating expenses:Net (loss) income-6,4574,167-13,261-5,412
Net (loss) income per share attributable to common stockholders:Basic-0.690.51-1.41-1
Net (loss) income per share attributable to common stockholders:Diluted-0.69-1-1.41-2.04
Weighted-average common shares outstanding:Basic9,381,3448,246,5829,381,3445,426,688
Weighted-average common shares outstanding:Diluted9,381,3448,455,2239,381,3446,160,967

Balance Sheet

June 30, 2026 — (in thousands, unaudited)

June 30, 2026December 31, 2025
Current assets:Cash and cash equivalents15,76520,734
Current assets:Short-term investments10,077
Current assets:Prepaid expenses and other current assets1,304727
Current assets:Total current assets17,06931,538
Current assets:Property and equipment, net3652
Current assets:Intangible assets, net291322
Current assets:Operating lease right-of-use assets104144
Current assets:Other non-current assets1717
Current assets:Total assets17,51732,073
Current liabilities:Accounts payable4,6383,219
Current liabilities:Accrued expenses4,3527,707
Current liabilities:Operating lease liabilities, current portion123116
Current liabilities:Total current liabilities9,11311,042
Current liabilities:Operating lease liabilities, net of current portion2285
Current liabilities:Total liabilities9,13511,127
Stockholders' equity:Common stock99
Stockholders' equity:Additional paid-in capital132,084131,379
Stockholders' equity:Accumulated other comprehensive income8
Stockholders' equity:Accumulated deficit-123,711-110,450
Stockholders' equity:Total stockholders' equity8,38220,946
Stockholders' equity:Total liabilities and stockholders' equity17,51732,073
Full release

Cautionary Statement Regarding Forward-looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of

1995. Examples of these forward-looking statements include statements concerning the anticipated benefits of Tvardi’s product candidates; its ongoing clinical trials and anticipated timing of reporting data from such trials; potential indications for its product candidates; its anticipated cash runway; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them.

Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are subject to a number of risks, including, among other things: the uncertainties associated with Tvardi’s product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the completion of clinical trials or safety or other complications related to its product candidates; the ability to obtain IND clearance for TTI-109 in UC on the timelines expected or at all; the requirement for additional capital to continue to advance these product candidates,... (truncated)rred since inception; Tvardi’s ability to initiate and complete ongoing and planned preclinical studies and clinical trials and advance its product candidates through clinical development; the timing of the availability of data from Tvardi’s clinical trials; the outcome of preclinical testing and clinical trials of Tvardi’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; Tvardi’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Tvardi’s product candidates; Tvardi’s anticipated cash runway; Tvardi’s ability to attract, hire, and retain skilled executive officers and employees; Tvardi’s ability to protect its intellectual property and proprietary technologies; Tvardi’s reliance on third parties, contract manufacturers, and contract research organizations; the possibility that Tvardi may be adversely affected by other economic, business, or competitive factors; risks associated with changes in applicable laws or regulations; those factors discussed in Tvardi’s filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Annual Report on Form 10-K for the year ended December 31, 2025, and

Tvardi’s other documents subsequently filed with or furnished to the SEC, all of which are available on the SEC’s website at www.sec.gov.

All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Contacts:

For Tvardi:

Tvardi Investor Relations ir@tvardi.com

PJ Kelleher

LifeSci Advisors

617-430-7579 pkelleher@lifesciadvisors.com

TVARDI THERAPEUTICS

Consolidated Balance Sheets

(in thousands, unaudited)

TVARDI THERAPEUTICS

Consolidated Statements of Operations

(in thousands, except share and per share data, unaudited)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Tvardi Therapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.